Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Find Exemplary Scents: An Extensive Aide - 2More than 3 million eye drops have been recalled from CVS, Walgreens and other national retailers. How to check if yours are safe
- 3Man triggers smoke bomb during failed crypto robbery
- 4Aluminum salts emerge as likely target as health officials scrutinize childhood vaccines
- 5Why is Jerome Powell being investigated? Making sense of the DOJ's probe into the Federal Reserve chair.
- Bird flu poses risk of pandemic worse than COVID, France's Institut Pasteur says
- German inflation soars to 2.7% in March as Iran war drives up prices
- Melodic Combination d: A Survey of \Unrecorded Music Energy\ Show
- Iran steps up executions as experts warn state killing being used to suppress political dissent
- She just became the first wheelchair user to travel to space
- What did the gov’t approve for Israel’s 2026 state budget?
- Quantum Computing’s Next Major Breakthroughs Could Come From Australia
- If everyone on Earth sat in the ocean at once, how much would sea level rise?
- Vote in favor of the subject that you see as generally captivating and intelligent!
